Eagle Pharmaceuticals Inc (EGRX) - Total Liabilities
Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has total liabilities worth $152.78 Million USD as of June 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Eagle Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Eagle Pharmaceuticals Inc - Total Liabilities Trend (2012–2022)
This chart illustrates how Eagle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Eagle Pharmaceuticals Inc assets under control.
Eagle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
Germany | €554.12 Million |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.94 Million |
|
Aurora Investment Trust plc
LSE:ARR
|
UK | GBX442.00K |
|
Marvel Discovery Corp
V:MARV
|
Canada | CA$1.86 Million |
|
Olympio Metals Ltd
AU:OLY
|
Australia | AU$810.12K |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
Australia | AU$2.94 Million |
|
Vaxtex Cotfab Limited
NSE:VCL
|
India | Rs143.82 Million |
|
Netcapital Inc
NASDAQ:NCPL
|
USA | $4.46 Million |
Liability Composition Analysis (2012–2022)
This chart breaks down Eagle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EGRX equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eagle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual total liabilities of Eagle Pharmaceuticals Inc from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $172.60 Million | +123.35% |
| 2021-12-31 | $77.28 Million | +15.03% |
| 2020-12-31 | $67.18 Million | -10.88% |
| 2019-12-31 | $75.38 Million | -3.16% |
| 2018-12-31 | $77.84 Million | -14.38% |
| 2017-12-31 | $90.92 Million | +45.83% |
| 2016-12-31 | $62.34 Million | +81.96% |
| 2015-12-31 | $34.26 Million | +68.65% |
| 2014-12-31 | $20.32 Million | +26.58% |
| 2013-12-31 | $16.05 Million | -25.48% |
| 2012-12-31 | $21.54 Million | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more